Article Text

Download PDFPDF
The monoclonal anti-CD25 antibody basiliximab for the treatment of progressive systemic sclerosis: an open-label study

Statistics from Altmetric.com

Footnotes

  • Funding The study was partly financially supported by a grant from Novartis, Germany.

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval This study was conducted with the approval of the local ethics committee.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.